Form 4: Sana Biotechnology Director Michelle Seitz Granted 80,000 Stock Options

Sana Biotechnology, Inc. (SANA) director Michelle Seitz has been granted 80,000 stock options with an exercise price of $2.55, aligning her interests with shareholder value.

Summary

• Michelle Seitz, a Director of Sana Biotechnology, Inc. (SANA), was granted 80,000 stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these stock options is $2.55 per share.
• The options vest and become exercisable as to 100% of the underlying shares on the earlier of June 5, 2026, or immediately prior to Sana's 2026 annual meeting of stockholders, provided continuous service.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Michelle Seitz beneficially owns 80,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine compensation grant to a director, which is generally a neutral to slightly positive event as it aligns management interests with shareholders. There are no negative implications or significant new information beyond the compensation detail.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value of Sana Biotechnology, Inc.
• The options have a long expiration date (June 4, 2035), providing a significant window for potential value realization.

Future Outlook

The document indicates a future vesting event for the granted stock options, contingent on the director's continuous service to the company through June 5, 2026, or the 2026 annual meeting.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and broader corporate sectors, serving as a key component of compensation packages designed to incentivize long-term commitment and align leadership interests with shareholder returns.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation mechanism within the biotechnology industry.
• Specific comparable companies, project values, or results are not detailed within this Form 4 filing, making a direct quantitative comparison to industry benchmarks for this specific grant size difficult based solely on this document.

Related Party Transactions

• Grant of 80,000 stock options to Michelle Seitz, a director of Sana Biotechnology, Inc., as part of her compensation package. This is a common form of related-party transaction for director remuneration.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial incentives with the company's performance, potentially benefiting shareholders through improved long-term value creation.

Next Steps

• The stock options are expected to vest on the earlier of June 5, 2026, or immediately prior to the 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Sana Biotechnology, SANA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Beneficial Ownership, Equity Compensation, Biotechnology